Page 212 - Read Online

Page 12 of 16 Landi et al. Neuroimmunol Neuroinflammation 2018;5:29 I http://dx.doi.org/10.20517/2347-8659.2018.35

TN, Chan TA. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
9. Supek F, Miñana B, Valcárcel J, Gabaldón T, Lehner B. Synonymous mutations frequently act as driver mutations in human cancers.
Cell 2014;156:1324-35.
10. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly
JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi
FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol
2014;32:1020-30.
11. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA,
Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet P-J, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn
R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an
anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):
a phase 2, single-arm trial. Lancet Oncol 2015;16:257-65.
12. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boy-
ault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Il-
icic T, Imbeaud S, Imielinski M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC,
Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL,
Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van
‘t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond
SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature
2013;500:415-21.
13. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N,
Mason G, Farah R, Afzal S, Yalon M, Rechavi G, Magimairajan V, Walsh MF, Constantini S, Dvir R, Elhasid R, Reddy A, Osborn M,
Sullivan M, Hansford J, Dodgshun A, Klauber-Demore N, Peterson L, Patel S, Lindhorst S, Atkinson J, Cohen Z, Laframboise R, Dirks P,
Taylor M, Malkin D, Albrecht S, Dudley RW, Jabado N, Hawkins CE, Shlien A, Tabori U. Immune checkpoint inhibition for hypermu-
tant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 2016;34:2206-11.
14. Lemos H, Huang L, Chandler PR, Mohamed E, Souza GR, Li L, Pacholczyk G, Barber GN, Hayakawa Y, Munn DH, Mellor AL. Acti-
vation of the STING adaptor attenuates experimental autoimmune encephalitis. J Immunol 2014;192:5571-8.
15. Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, Chouaib S. Hypoxia: a key player in antitumor immune response. A re-
view in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol 2015;309:C569-79.
16. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and
polarization. Trends Immunol 2004;25:677-86.
17. Chatzinikolaou G, Karakasilioti I, Garinis GA. DNA damage and innate immunity: links and trade-offs. Trends Immu-
nol2014;35:429-35.
18. Woods D, Turchi JJ. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther
2013;14:379-89.
19. Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids
2010;2010:543531.
20. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.
Nature 2005;436:1186-90.
21. Liontos M, Anastasiou I, Bamias A, Dimopoulos MA. DNA damage, tumor mutational load and their impact on immune responses
against cancer. Ann Transl Med 2016;4:264.
22. Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. Front Genet 2015;6:157.
23. Bibault JE, Tinhofer I. The role of next-generation sequencing in tumoral radiosensitivity prediction. Clin Transl Radiat Oncol
2017;3:16-20.
24. Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immu-
nother 2018;14:839-46.
25. Lawler SE, Speranza M, Cho C, Chiocca E. Oncolytic viruses in cancer treatment: a review. JAMA Oncol 2017;3:841-9.
26. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014;14:559-67.
27. Gromeier M, Nair SK. Recombinant poliovirus for cancer immunotherapy. Ann Rev Med 2018;69:289-99.
28. Duke University. Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children. ClinicalTrials.gov Identifier: NCT03043391.
29. Tejada S, Alonso M, Patiño A, Fueyo J, Gomez-Manzano C, Diez-Valle R. Phase I trial of DNX-2401 for diffuse intrinsic pontine glio-
ma newly diagnosed in pediatric patients. Neurosurgery 2017; doi: 10.1093/neuros/nyx507.
30. Mayo Clinic. Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Re-
fractory Brain Tumors. ClinicalTrials.gov Identifier: NCT02444546.
31. Waters AM, Johnston JM, Reddy AT, Fiveash J, Madan-Swain A, Kachurak K, Bag AK, Gillespie GY, Markert JM, Friedman GK. Ra-
tionale and design of a phase 1 clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or
recurrent malignant supratentorial brain tumors. Hum Gene Ther Clin Dev 2017;28:7-16.
32. University of Alabama at Birmingham. HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent
Supratentorial Brain Tumors. ClinicalTrials.gov Identifier: NCT02457845.
33. Csatary LK, Bakács T. Use of newcastle disease virus vaccine (mth-68/h) in a patient with high-grade glioblastoma. JAMA
1999;281:1588-9.
34. Van Gool S, Lulei M, Schirrmacher V, Stuecker W. DIPG-10. Multimodal immunotherapy as part of multimodal treatment for DIPG.
Neuro Oncol 2017;19:iv6-7.